Clinical significance of an anti-Di^b assessed by flow cytometry

Abstract

Although antibodies to the Di b antigen are generally considered to be of potential clinical significance, we know of no reports assessing the clinical significance of anti-Di b (in vivo or in vitro). We report on an 88-year-old Japanese male gastrectomy patient who had alloanti-Di b . After transfusion of two Di(b-) units, three Di(b+) units had to be transfused, and there were no clinical signs of acute hemolysis. Di(b+) RBC survival was followed retrospectively by flow cytometry. On days 1, 7, and 10, the percent of circulating Di(b+) RBCs was determined to be 39, 30, and 11 percent, respectively, compared to an expected 49, 43, and 41 percent based on calculations. The Di(b+) RBCs appear to have been tolerated for about 6 days, then were removed from the circulation. Direct anti-IgG tests were 1-2+ mixed field with all posttransfusion samples. Monocyte monolayer assays (MMAs), which have been reported to predict the clinical significance of alloantibodies, gave borderline positive results. MMA results using sera from days 0, 3, and 9 were 2.7 and 5.5, 0.8 and 4.8, and 3.0 and 3.7 percent, respectively, without and with added fresh normal serum as a source of complement (clinical significance = > 3% reactivity). The subclass of the anti-Di b was IgG1. This is the first documentation of the clinical significance of an anti-Di b . Immunohematology 1997;13:93-96.